- Author:
Min Ji JEON
1
;
Won Gu KIM
;
Tae Yong KIM
;
Young Kee SHONG
;
Won Bae KIM
Author Information
- Publication Type:Review Article
- From:Endocrinology and Metabolism 2021;36(4):717-724
- CountryRepublic of Korea
- Language:English
- Abstract: Active surveillance (AS) for low-risk papillary thyroid microcarcinoma (PTMC) has been accepted worldwide as safe and effective. Despite the growing acceptance of AS in the management of low-risk PTMCs, there are barriers to AS in real clinical settings, and it is important to understand and establish appropriate AS protocol from initial evaluation to follow-up. PTMC management strategies should be decided upon after careful consideration of patient and tumor characteristics by a multidisciplinary team of thyroid cancer specialists. Patients should understand the risks and benefits of AS, participate in decision-making and follow structured monitoring strategies. In this review, we discuss clinical outcomes of AS from previous studies, optimal indications and follow-up strategies for AS, and unresolved questions about AS.